LC-MS/MS方法测定人血浆中奥美沙坦

LC-MS/MS assays to determine olmesartan concentration in human plasma

AIM: To develop and validate a liquid chromatography-tandem mass spectrometric method (LC-MS/MS) for quantifying olmesartan in human plasma. METHODS: Telmisartan was added as the internal standard,the plasma sample was extracted using acetonitrile and then separated on a Waters Xterra MS C18(2.1 mm×50 mm,5 μm)column and the column temperature was set at 40 ℃. The mobile phase consisted of acetonitrile-0.1% formic acid water solution(50∶50,v/v),the flow rate was 0.3 mL/min. The ionization was optimized using ESI (+) and enhanced selectivity was achieved using tandem mass spectrometric analysis via MRM functions, the ion of m/z 448.27-429.7 and m/z 516.43-497.8, 276.5 was used to qualify olmesartan and telmisartan, respectively. RESULTS: The concentration range of olmesartan was 2.25-2280 ng/mL, with a good linearity. The lower limit of quantitation (LLOQ) of olmesartan in plasma was 2.250 ng/mL. The extracted recovery was >60%, the relative recovery was 99%-105%. The intra-and inter-day RSD were <15%. CONCLUSION: It can be used for determination of olmesartan plasma concentration and pharmacokinetic study as a sensitive, simple and accurate method.

AIM： To develop and validate a liquid chromatographytandem mass spectrometric method （IE-MS/MS） for quantifying olmesartan in human plasma. METHODS： Telmisartan was added as the internal standard, the plasma sample was extracted using acetonitrile and then separated on a Waters Xterra MS C18 （2.1 mm × 50 mm,5 μm）column and the column temperature was set at 40 ℃. The mobile phase consisted of acetonitrile-0.1% formic acid water solution（50 ： 50, v/v）, the flow rate was 0.3 mL/min. The ionization was optimized using ESI （ ＋ ） and enhanced selectivity was achieved using tandem mass spectrometric analysis via MRM functions, the ion of m/z 448.27 - 429.7 and m/z 516.43 - 497.8, 276.5 was used to qualify olmesartan and telmisartan, respectively.